Autoantibody signature for the serologic detection of ovarian cancer

Karen Anderson, Daniel W. Cramer, Sahar Sibani, Garrick Wallstrom, Jessica Wong, Jin Park, Ji Qiu, Allison Vitonis, Joshua LaBaer

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Sera from patients with ovarian cancer contain autoantibodies (AAb) to tumor-derived proteins that are potential biomarkers for early detection. To detect AAb, we probed high-density programmable protein microarrays (NAPPA) expressing 5177 candidate tumor antigens with sera from patients with serous ovarian cancer (n = 34 cases/30 controls) and measured bound IgG. Of these, 741 antigens were selected and probed with an independent set of ovarian cancer sera (n = 60 cases/60 controls). Twelve potential autoantigens were identified with sensitivities ranging from 13 to 22% at >93% specificity. These were retested using a Luminex bead array using 60 cases and 60 controls, with sensitivities ranging from 0 to 31.7% at 95% specificity. Three AAb (p53, PTPRA, and PTGFR) had area under the curve (AUC) levels >60% (p < 0.01), with the partial AUC (SPAUC) over 5 times greater than for a nondiscriminating test (p < 0.01). Using a panel of the top three AAb (p53, PTPRA, and PTGFR), if at least two AAb were positive, then the sensitivity was 23.3% at 98.3% specificity. AAb to at least one of these top three antigens were also detected in 7/20 sera (35%) of patients with low CA 125 levels and 0/15 controls. AAb to p53, PTPRA, and PTGFR are potential biomarkers for the early detection of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)578-586
Number of pages9
JournalJournal of Proteome Research
Volume14
Issue number1
DOIs
StatePublished - Jan 2 2015

Fingerprint

Autoantibodies
Ovarian Neoplasms
Biomarkers
Serum
Area Under Curve
Antigens
Protein Array Analysis
Autoantigens
Neoplasm Antigens
Microarrays
Early Detection of Cancer
Tumors
Proteins
Immunoglobulin G
Neoplasms

Keywords

  • autoantibodies
  • biomarker
  • Ovarian cancer
  • protein microarrays
  • proteomics

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Autoantibody signature for the serologic detection of ovarian cancer. / Anderson, Karen; Cramer, Daniel W.; Sibani, Sahar; Wallstrom, Garrick; Wong, Jessica; Park, Jin; Qiu, Ji; Vitonis, Allison; LaBaer, Joshua.

In: Journal of Proteome Research, Vol. 14, No. 1, 02.01.2015, p. 578-586.

Research output: Contribution to journalArticle

Anderson, Karen ; Cramer, Daniel W. ; Sibani, Sahar ; Wallstrom, Garrick ; Wong, Jessica ; Park, Jin ; Qiu, Ji ; Vitonis, Allison ; LaBaer, Joshua. / Autoantibody signature for the serologic detection of ovarian cancer. In: Journal of Proteome Research. 2015 ; Vol. 14, No. 1. pp. 578-586.
@article{45e71c9460544b65bbecbe459e3f7a33,
title = "Autoantibody signature for the serologic detection of ovarian cancer",
abstract = "Sera from patients with ovarian cancer contain autoantibodies (AAb) to tumor-derived proteins that are potential biomarkers for early detection. To detect AAb, we probed high-density programmable protein microarrays (NAPPA) expressing 5177 candidate tumor antigens with sera from patients with serous ovarian cancer (n = 34 cases/30 controls) and measured bound IgG. Of these, 741 antigens were selected and probed with an independent set of ovarian cancer sera (n = 60 cases/60 controls). Twelve potential autoantigens were identified with sensitivities ranging from 13 to 22{\%} at >93{\%} specificity. These were retested using a Luminex bead array using 60 cases and 60 controls, with sensitivities ranging from 0 to 31.7{\%} at 95{\%} specificity. Three AAb (p53, PTPRA, and PTGFR) had area under the curve (AUC) levels >60{\%} (p < 0.01), with the partial AUC (SPAUC) over 5 times greater than for a nondiscriminating test (p < 0.01). Using a panel of the top three AAb (p53, PTPRA, and PTGFR), if at least two AAb were positive, then the sensitivity was 23.3{\%} at 98.3{\%} specificity. AAb to at least one of these top three antigens were also detected in 7/20 sera (35{\%}) of patients with low CA 125 levels and 0/15 controls. AAb to p53, PTPRA, and PTGFR are potential biomarkers for the early detection of ovarian cancer.",
keywords = "autoantibodies, biomarker, Ovarian cancer, protein microarrays, proteomics",
author = "Karen Anderson and Cramer, {Daniel W.} and Sahar Sibani and Garrick Wallstrom and Jessica Wong and Jin Park and Ji Qiu and Allison Vitonis and Joshua LaBaer",
year = "2015",
month = "1",
day = "2",
doi = "10.1021/pr500908n",
language = "English (US)",
volume = "14",
pages = "578--586",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Autoantibody signature for the serologic detection of ovarian cancer

AU - Anderson, Karen

AU - Cramer, Daniel W.

AU - Sibani, Sahar

AU - Wallstrom, Garrick

AU - Wong, Jessica

AU - Park, Jin

AU - Qiu, Ji

AU - Vitonis, Allison

AU - LaBaer, Joshua

PY - 2015/1/2

Y1 - 2015/1/2

N2 - Sera from patients with ovarian cancer contain autoantibodies (AAb) to tumor-derived proteins that are potential biomarkers for early detection. To detect AAb, we probed high-density programmable protein microarrays (NAPPA) expressing 5177 candidate tumor antigens with sera from patients with serous ovarian cancer (n = 34 cases/30 controls) and measured bound IgG. Of these, 741 antigens were selected and probed with an independent set of ovarian cancer sera (n = 60 cases/60 controls). Twelve potential autoantigens were identified with sensitivities ranging from 13 to 22% at >93% specificity. These were retested using a Luminex bead array using 60 cases and 60 controls, with sensitivities ranging from 0 to 31.7% at 95% specificity. Three AAb (p53, PTPRA, and PTGFR) had area under the curve (AUC) levels >60% (p < 0.01), with the partial AUC (SPAUC) over 5 times greater than for a nondiscriminating test (p < 0.01). Using a panel of the top three AAb (p53, PTPRA, and PTGFR), if at least two AAb were positive, then the sensitivity was 23.3% at 98.3% specificity. AAb to at least one of these top three antigens were also detected in 7/20 sera (35%) of patients with low CA 125 levels and 0/15 controls. AAb to p53, PTPRA, and PTGFR are potential biomarkers for the early detection of ovarian cancer.

AB - Sera from patients with ovarian cancer contain autoantibodies (AAb) to tumor-derived proteins that are potential biomarkers for early detection. To detect AAb, we probed high-density programmable protein microarrays (NAPPA) expressing 5177 candidate tumor antigens with sera from patients with serous ovarian cancer (n = 34 cases/30 controls) and measured bound IgG. Of these, 741 antigens were selected and probed with an independent set of ovarian cancer sera (n = 60 cases/60 controls). Twelve potential autoantigens were identified with sensitivities ranging from 13 to 22% at >93% specificity. These were retested using a Luminex bead array using 60 cases and 60 controls, with sensitivities ranging from 0 to 31.7% at 95% specificity. Three AAb (p53, PTPRA, and PTGFR) had area under the curve (AUC) levels >60% (p < 0.01), with the partial AUC (SPAUC) over 5 times greater than for a nondiscriminating test (p < 0.01). Using a panel of the top three AAb (p53, PTPRA, and PTGFR), if at least two AAb were positive, then the sensitivity was 23.3% at 98.3% specificity. AAb to at least one of these top three antigens were also detected in 7/20 sera (35%) of patients with low CA 125 levels and 0/15 controls. AAb to p53, PTPRA, and PTGFR are potential biomarkers for the early detection of ovarian cancer.

KW - autoantibodies

KW - biomarker

KW - Ovarian cancer

KW - protein microarrays

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=84920269097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920269097&partnerID=8YFLogxK

U2 - 10.1021/pr500908n

DO - 10.1021/pr500908n

M3 - Article

VL - 14

SP - 578

EP - 586

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 1

ER -